natgillin/translations-raw huggingface dataset:
Member States shall request the submission of further studies to address the potential endocrine disrupting properties of procymidone within two years after the adoption of the Test Guidelines on endocrine disruption by the Organisation for Economic Cooperation and Development (OECD).
Države članice zahtevajo predložitev nadaljnjih študij o potencialnih motnjah endokrinega sistema, ki jih povzroča procimidon, v dveh letih po sprejetju smernic za testiranje motenj endokrinega sistema Organizacije za gospodarsko sodelovanje in razvoj (OECD).
They shall ensure that the notifier at whose request procymidone has been included in this Annex provide such studies to the Commission within two years of the adoption of the above test guidelines.’
Zagotovijo, da prijavitelj, na katerega zahtevo je bil procimidon vključen v to prilogo, take študije predloži Komisiji v 2 letih po sprejetju zgornjih smernic za testiranje.“
Commission Directive 2006/133/EC
Direktiva Komisije 2006/133/ES
amending Council Directive 91/414/EEC to include flusilazole as active substance
o spremembi Direktive Sveta 91/414/EGS glede vključitve flusilazola kot aktivne snovi
That list includes flusilazole.
Ta seznam vključuje flusilazol.
For flusilazole the effects on human health and the environment have been assessed in accordance with the provisions laid down in Regulation (EEC) No 3600/92 for a range of uses proposed by the notifier.
Vpliv flusilazola na zdravje ljudi in na okolje se je presojal v skladu z določbami Uredbe (EGS) št. 3600/92 za vrste uporabe, ki jih je predlagal prijavitelj.
By Commission Regulation (EC) No 933/94 of 27 April 1994 laying down the active substances of plant protection products and designating the Rapporteur Member State for the implementation of Commission Regulation (EEC) No 3600/92 [3], Ireland was designated as Rapporteur Member State.
Z Uredbo Komisije (ES) št. 933/94 z dne 27. aprila 1994 o določitvi aktivnih snovi fitofarmacevtskih sredstev in imenovanju držav članic poročevalk za izvajanje Uredbe Komisije (EGS) št. 3600/92 [3] je bila za državo članico poročevalko imenovana Irska.
Ireland submitted the relevant assessment report and recommendations to the Commission on 30 April 1996 in accordance with Article 7(1)(c) of Regulation (EEC) No 3600/92.
Irska je predložila Komisiji ustrezno poročilo o oceni in priporočila 30. aprila 1996 v skladu s členom 7(1)(c) Uredbe (EGS) št. 3600/92.
As regards flusilazole two questions were submitted to the Scientific Committee on Plants (the Scientific Committee).
Za flusilazol sta bili Znanstvenemu odboru za rastline (Znanstveni odbor) predloženi dve vprašanji.
The first concerned the adequacy of the proposed NOEC (No Observed Effect Concentration) for ensuring a sufficient protection from adverse effects on reproduction and, more generally, the comparative sensitivity of the early life stage test compared to the full fish life cycle study.
Prvo vprašanje se je nanašalo na primernost predlagane koncentracije brez opaznega učinka (NOEC) za zagotavljanje zadostne zaščite pred škodljivimi učinki za razmnoževanje in bolj splošno, primerjalno občutljivost preskusa v zgodnjem življenjskem obdobju v primerjavi s študijo celotnega življenjskega cikla rib.
The second question related to the potential impact on organic matter decomposition.
Drugo vprašanje se je nanašalo na možni vpliv na razgradnjo organskih snovi.
In both cases, the recommendations of the Scientific Committee [4] have been taken into consideration in formulating this Directive and the relevant review report.
V obeh primerih so bila pri oblikovanju direktive in ustreznega poročila o pregledu upoštevana priporočila Znanstvenega odbora [4].
It has appeared from the various examinations made that plant protection products containing flusilazole may be expected to satisfy the requirements laid down in Article 5(1)(a) and (b) of Directive 91/414/EEC, with regard to the uses which were examined and detailed in the Commission review report, provided that adequate risk mitigation measures are applied.
Različne preiskave so pokazale, da je za fitofarmacevtska sredstva, ki vsebujejo flusilazol, mogoče pričakovati, da izpolnjujejo zahteve iz člena 5(1)(a) in (b) Direktive 91/414/EGS, zlasti v zvezi z vrstami uporabe, ki so bile proučene in podrobno navedene v poročilu Komisije o pregledu, pod pogojem, da se uporabljajo ustrezni ukrepi za zmanjšanje tveganja.
As flusilazole is a hazardous substance, its use should not be unrestricted.
Ker je flusilazol nevarna snov, njegova uporaba ne bi smela biti neomejena.
Applying the precautionary principle, and taking into account the current state of scientific knowledge, risk mitigation measures should be imposed in order to achieve the high level of protection of human and animal health and the environment chosen in the Community.
Ob uporabi previdnostnega načela in upoštevanju trenutnih znanstvenih spoznanj bi bilo treba uvesti ukrepe za zmanjšanje tveganja, da bi zaščitili zdravje ljudi in živali ter izbrano okolje v Skupnosti.
The original measures presented to the Standing Committee on the Food Chain and Animal Health, proposed the restriction of the inclusion period to seven years, so that Member States would give priority to reviewing plant protection products already on the market containing flusilazole.
Prvotni ukrepi, predstavljeni Stalnemu odboru za prehransko verigo ljudi in zdravstveno varstvo živali, predlagajo omejitev obdobja vključitve na sedem let, tako da bi države članice prednostno pregledale fitofarmacevtska sredstva, ki so že na trgu in vsebujejo flusilazol.
In order to avoid discrepancies in the high level of protection sought, the inclusion in Annex I to Directive 91/414/EEC was intended to be limited to the uses of flusilazole that have been actually assessed within the Community evaluation and for which the proposed uses were considered to comply with the conditions of Directive 91/414/EEC.
Da bi se izognili odstopanjem v zahtevani visoki stopnji zaščite, je bilo predvideno, da bo vključitev v Prilogo I k Direktivi 91/414/EGS omejena na vrste uporabe flusilazola, ki so bile dejansko ocenjene v okviru ocene Skupnosti, za katere je bilo ocenjeno, da so v skladu s pogoji Direktive 91/414/EGS.
This implies that other uses, which were not or only partially covered by this assessment, had first to be subject to a complete assessment, before their inclusion in Annex I of Directive 91/414/EEC could be considered.
To pomeni, da je bilo treba za druge vrste uporabe, ki v tej oceni niso bile zajete ali so bile zajete le delno, najprej opraviti celovito oceno pred njihovo vključitvijo v Prilogo I k Direktivi 91/414/EGS.
Finally, due to the hazardous nature of flusilazole, it was considered necessary to provide for a minimum harmonisation at Community level of certain risk mitigation measures that were to be applied by Member States when granting authorisations.
Poleg tega se je zaradi nevarne narave flusilazola štelo, da je treba na ravni Skupnosti poskrbeti za minimalno uskladitev nekaterih ukrepov za zmanjšanje tveganja, ki so jih morale države članice izvajati pri podeljevanju registracij.
Concerns expressed by several Member States reflect their judgment that additional restrictions are necessary to reduce the risk to a level that can be considered acceptable and consistent with the high level of protection that is sought within the Community.
Pomisleki, ki jih je izrazilo več držav članic, kažejo njihovo presojo, da so potrebne dodatne omejitve za zmanjšanje tveganja na raven, ki se lahko šteje za sprejemljivo in skladno z visoko ravnjo zaščite, za katero si prizadeva Skupnost.
At present, it is a question of risk management to set the adequate level of safety and protection for the continued production, commercialisation and use of flusilazole.
Trenutno je odvisno od obvladovanja tveganja, da določi ustrezno stopnjo varnosti in zaščite za nemoteno proizvodnjo, komercializacijo in uporabo flusilazola.
In order to correctly reflect the high level of protection of human and animal health and a sustainable environment sought in the Community, it considered appropriate, in addition to the principles set out in recital 6, to further reduce the period of inclusion to 18 months instead of seven years.
Da bi bila pravilno razvidna visoka stopnja varovanja zdravja ljudi in zdravja živali ter trajnostnega razvoja okolja, za katero si Skupnost prizadeva, se šteje za ustrezno, da se poleg načel iz uvodne izjave 6 nadalje skrajša rok vključitve na 18 mesecev namesto sedem let.
It may be expected that plant protection products containing flusilazole satisfy the requirements laid down in Article 5(1)(a) and (b) of Directive 91/414/EEC, with regard to the uses which were examined and detailed in the Commission review report and providing that the necessary risk mitigation measures are applied.
Pričakuje se lahko, da fitofarmacevtska sredstva, ki vsebujejo flusilazol, izpolnjujejo zahteve iz člena 5(1)(a) in (b) Direktive 91/414/EGS v zvezi z vrstami uporabe, ki so bile proučene in podrobno navedene v poročilu Komisije o pregledu, pod pogojem da se uporabljajo ustrezni ukrepi za zmanjšanje tveganja.
Without prejudice to the conclusion that plant protection products containing flusilazole may be expected to satisfy the requirements laid down in Article 5(1)(a) and (b) of Directive 91/414/EEC, it is appropriate to obtain further information on certain specific points.
Brez poseganja v sklep, da je od fitofarmacevtskih sredstev, ki vsebujejo flusilazol, mogoče pričakovati, da izpolnjujejo zahteve iz člena 5(1)(a) in (b) Direktive 91/414/EGS, je ustrezno pridobiti nadaljnje informacije o določenih podrobnostih.
The potential endocrine disrupting properties of flusilazole have been assessed in tests which follow the best currently available practice.
Potencialne motnje endokrinega sistema, ki jih povzroča flusilazol, so bile ocenjene s testom, ki izhaja iz najboljše prakse, ki je trenutno na voljo.
Therefore it is appropriate to require that flusilazole should be subjected to such further testing as soon as agreed OECD Test Guidelines exist and that such studies should be presented by the notifier.
Zato je primerno zahtevati, da se opravijo taki nadaljnji testi za flusilazol, takoj ko bodo na voljo dogovorjene smernice za testiranje, in da prijavitelj predloži takšne študije.
In addition, Member States should require authorisation holders to provide information on the use of flusilazole including any information on incidences on operator health.
Poleg tega bi morale države članice od imetnikov registracij zahtevati, da predložijo informacije o uporabi flusilazola vključno z morebitnimi informacijami o vplivih na zdravje delavcev.
As with all substances included in Annex I to Directive 91/414/EEC, the status of flusilazole could be reviewed under Article 5(5) of that Directive in the light of any new data becoming available.
Tako kot pri vseh snoveh, vključenih v Prilogo I k Direktivi 91/414/EGS, naj bi bilo mogoče status flusilazola pregledati po členu 5(5) navedene direktive na podlagi novih podatkov, ki postanejo dostopni.
Without prejudice to the obligations defined by Directive 91/414/EEC as a consequence of including an active substance in Annex I, Member States should be allowed a period of six months after inclusion to review existing authorisations of plant protection products containing flusilazole to ensure that the requirements laid down by Directive 91/414/EEC, in particular in its Article 13 and the relevant conditions set out in Annex I, are satisfied. Member States should vary, replace or withdraw, as appropriate, existing authorisations in accordance with the provisions of Directive 91/414/EEC.
Brez poseganja v obveznosti, opredeljene v Direktivi 91/414/EGS kot posledica vključitve aktivne snovi v Prilogo I, je državam članicam treba dovoliti, da v roku 6 mesecev po vključitvi snovi pregledajo obstoječe registracije za fitofarmacevtska sredstva, ki vsebujejo flusilazol, da se zagotovi izpolnjevanje zahtev iz Direktive 91/414/EGS, zlasti iz člena 13 Direktive, in ustreznih pogojev iz Priloge I. Države članice v skladu z določbami Direktive 91/414/EGS po potrebi spremenijo, nadomestijo ali prekličejo obstoječe registracije.
Given the hazardous properties of flusilazole, the period for Member States to verify whether plant protection products containing flusilazole, alone or in combination with other authorised active substances, comply with the provisions of Annex VI should not exceed 18 months.
Zaradi nevarnih lastnosti flusilazola rok, v katerem države članice preverijo, ali fitofarmacevtska sredstva, ki vsebujejo flusilazol, ali sam ali v kombinaciji z drugimi registriranimi aktivnimi snovmi, izpolnjujejo zahteve iz Priloge VI, ne bi smel biti daljši od 18 mesecev.
The Standing Committee on the Food Chain and Animal Health did not deliver an opinion within the time limit laid down by its Chairman and the Commission therefore submitted to the Council a proposal relating to these measures.
Stalni odbor za prehranjevalno verigo in zdravje živali ni dal mnenja v roku, ki ga je določil njegov predsednik in zato je Komisija predložila Svetu predlog v zvezi s temi ukrepi.
On the expiry of the period laid down in the second subparagraph of Article 19(2) of Directive 91/414/EEC, the Council had neither adopted the proposed implementing act nor indicated its opposition to the proposal for implementing measures and it is accordingly for the Commission to adopt these measures,
Ob izteku obdobja, določenega v drugem pododstavku člena 19(2) Direktive 91/414/EGS, Svet ni niti sprejel predlaganega izvedbenega akta, niti navedel svojega nasprotovanja predlogu za izvedbene ukrepe in zato Komisija sprejme te ukrepe –
Member States shall in accordance with Directive 91/414/EEC, where necessary, amend or withdraw existing authorisations for plant protection products containing flusilazole as an active substance by 30 June 2007.
Države članice v skladu z Direktivo 91/414/EGS do 30. junija 2007 po potrebi spremenijo ali prekličejo obstoječe registracije za fitofarmacevtska sredstva, ki kot aktivno snov vsebujejo flusilazol.
By that date they shall in particular verify that the conditions in Annex I to that Directive relating to flusilazole are met, with the exception of those identified in part B of the entry concerning that active substance, and that the holder of the authorisation has, or has access to, a dossier satisfying the requirements of Annex II to that Directive in accordance with the conditions of Article 13.
Do navedenega datuma zlasti preverijo, ali so izpolnjeni pogoji iz Priloge I k navedeni direktivi v zvezi s flusilazolom, z izjemo tistih iz dela B besedila, ki se nanaša na navedeno aktivno snov, in ali ima imetnik registracije dokumentacijo ali dostop do dokumentacije, ki izpolnjuje zahteve iz Priloge II k navedeni direktivi v skladu s pogoji iz člena 13.
By derogation from paragraph 1, for each authorised plant protection product containing flusilazole, Member States shall re-evaluate the product in accordance with the uniform principles provided for in Annex VI to Directive 91/414/EEC, on the basis of a dossier satisfying the requirements of Annex III to that Directive and taking into account part B of the entry in Annex I to that Directive concerning flusilazole.
Z odstopanjem od odstavka 1 države članice znova ocenijo vsako registrirano fitofarmacevtsko sredstvo, ki vsebuje flusilazol, v skladu z enotnimi načeli iz Priloge VI k Direktivi 91/414/EGS na podlagi dokumentacije, ki izpolnjuje zahteve iz Priloge III k navedeni direktivi, in ob upoštevanju dela B vpisa v Prilogo I k navedeni direktivi v zvezi s flusilazolom.
Following that determination Member States shall for products containing flusilazole, where necessary, amend or withdraw the authorisation by 30 June 2008.
Po tej oceni države članice za sredstva, ki vsebujejo flusilazol, registracijo do 30. junija 2008 po potrebi spremenijo ali prekličejo.
Opinion of the Scientific Committee on Plants on specific questions from the Commission concerning the evaluation of flusilazole in the context of Council Directive 91/414/EEC (Opinion adopted by the Scientific Committee on Plants on 18 July 2002).
Mnenje Znanstvenega odbora za rastline o posebnih vprašanjih Komisije glede ocene flusilazola v smislu Direktive Sveta 91/414/EGS (Mnenje, ki ga je Znanstveni odbor za rastline sprejel 18. julija 2002).
The following entries shall be added at the end of the table in Annex I to Directive 91/414/EEC:
Na konec tabele v Prilogi I k Direktivi 91/414/EGS se doda naslednji vpis:
CAS No 85509-19-9
Št. CAS 85509-19-9
CIPAC No 435
Št. CIPAC 435
Bis(4-fluorophenyl)(methyl) (1H-1,2.4-triazol-1-ylmethyl)silane
Bis(4-fluorofenil)(metil)(1H-1,2.4-triazol-1-ilmetil) silan
cereals other than rice,
žita, razen riža
maize,
koruzo
rape seed,
oljno repico
sugar beet,
sladkorno peso
at rates not exceeding 200 g active substance per hectare per application.
kjer količina ne presega 200 g aktivne snovi na hektar ob posamičnem nanosu.
knapsack and hand-held applications, neither by amateur nor by professional users,
nanašanje z oprtnimi ali ročnimi škropilnicami amaterskih ali poklicnih uporabnikov,
An appropriate distance must be kept between treated areas and surface water bodies.
Ohranjena mora biti zadostna razdalja med območji nanosa in površinskimi vodami.
operators, who must wear suitable protective clothing, in particular gloves, coveralls, rubber boots and face protection or safety glasses during mixing, loading, application and cleaning of the equipment, unless the exposure to the substance is adequately precluded by the design and construction of the equipment itself or by the mounting of specific protective components on such equipment.
delavcev, ki morajo med mešanjem, nakladanjem, nanašanjem in čiščenjem opreme nositi ustrezna zaščitna oblačila, zlasti rokavice, hlače z oprsnikom, gumijaste škornje ter zaščito obraza ali zaščitna očala, razen če izpostavljenost snovi ustrezno onemogočajo zasnova in izvedba opreme same ali posebni zaščitni deli na taki opremi.
For the implementation of the uniform principles of Annex VI, the conclusions of the review report on flusilazole, and in particular Appendices I and II thereof, shall be taken into account.
Za izvajanje enotnih načel iz Priloge VI se upoštevajo sklepi poročila o pregledu za flusilazol in zlasti dodatkov I in II.
Member States may require that elements, such as sales data and a survey of use patterns, are provided so that a realistic picture of the use conditions and the possible toxicological impact of flusilazole can be obtained.
Države članice lahko zahtevajo navedbo posameznih podrobnosti, kot so podatki o prodaji in pregled vzorcev uporabe, tako da se lahko pridobi realistična slika o pogojih uporabe in morebitnem toksikološkem učinku flusilazola.
Member States shall request the submission of further studies to address the potential endocrine disrupting properties of flusilazole within two years after the adoption of the Test Guidelines on endocrine disruption by the Organisation for Economic Cooperation and Development (OECD).
Države članice zahtevajo predložitev nadaljnjih študij o potencialnih motnjah endokrinega sistema, ki jih povzroča flusilazol, v dveh letih po sprejetju smernic za testiranje motenj endokrinega sistema Organizacije za gospodarsko sodelovanje in razvoj (OECD).
They shall ensure that the notifier at whose request flusilazole has been included in this Annex provide such studies to the Commission within two years of the adoption of the above test guidelines.’
Zagotovijo, da prijavitelj, na katerega zahtevo je bil flusilazol vključen v to prilogo, take študije predloži Komisiji v 2 letih po sprejetju zgornjih smernic za testiranje.“
Commission Directive 2006/134/EC
Direktiva Komisije 2006/134/ES
amending Council Directive 91/414/EEC to include fenarimol as active substance
o spremembi Direktive Sveta 91/414/EGS glede vključitve fenarimola kot aktivne snovi
That list includes fenarimol.
Ta seznam vključuje fenarimol.
For fenarimol the effects on human health and the environment have been assessed in accordance with the provisions laid down in Regulation (EEC) No 3600/92 for a range of uses proposed by the notifier.
Vpliv fenarimola na zdravje ljudi in okolje je bil predmet presoje v skladu z določbami Uredbe (EGS) št. 3600/92 za vrste uporab, ki jih je predlagal prijavitelj.
By Commission Regulation (EC) No 933/94 of 27 April 1994 laying down the active substances of plant protection products and designating the Rapporteur Member State for the implementation of Commission Regulation (EEC) No 3600/92 [3], the United Kingdom was designated as Rapporteur Member State.
Z Uredbo Komisije (ES) št. 933/94 z dne 27. aprila 1994 o določitvi aktivnih snovi fitofarmacevtskih sredstev in imenovanju držav članic poročevalk za izvajanje Uredbe Komisije (EGS) št. 3600/92 [3] je bilo za državo članico poročevalko imenovano Združeno kraljestvo.
The United Kingdom submitted the relevant assessment report and recommendations to the Commission on 30 April 1996 in accordance with Article 7(1)(c) of Regulation (EEC) No 3600/92.
Združeno kraljestvo je 30. aprila 1996 predložilo Komisiji ustrezno poročilo o oceni in priporočila v skladu s členom 7(1)(c) Uredbe (EGS) št. 3600/92.
As regards fenarimol two questions were submitted to the Scientific Committee on Plants (the Scientific Committee).
Za fenarimol sta bili Znanstvenemu odboru za rastline (Znanstvenemu odboru) predloženi dve vprašanji.
The Scientific Committee was asked to comment on the interpretation of the multi-generation studies and to consider the aromatase inhibition effects of fenarimol.
Znanstveni odbor je bil zaprošen, da pove svoje mnenje o razlagi večgeneracijskih raziskav in da prouči zaviralne učinke fenarimola na aromatazo.
In addition its opinion was sought on the establishment of a reliable acceptable daily intake (ADI) and acceptable operator exposure level (AOEL) [4].
Poleg tega je bil zaprošen za mnenje o določitvi zanesljivega sprejemljivega dnevnega vnosa (ADI) in dopustne ravni izpostavljenosti uporabnika (AOEL) [4].
The Scientific Committee concluded that the effects of fenarimol on male fertility seen in rats had to be considered relevant for human risk assessment although man is less sensitive than rats to the effects of aromatase inhibition.
Znanstveni odbor je sklenil, da je treba učinke fenarimola na moško plodnost, ugotovljene pri podganah, šteti za pomemben dejavnik pri oceni tveganja za ljudi, čeprav so ljudje manj dovzetni za inhibicijo aromataze kot podgane.
It also concluded that the effects of fenarimol on parturition in rats could be considered as not relevant for human risk assessment.
Sklenil je tudi, da bi bilo mogoče učinke fenarimola na kotitev pri podganah šteti za nepomemben dejavnik pri oceni tveganja za ljudi.
It was further concluded that, apart from male-mediated reduced fertility and effects associated with delayed parturition, there was no convincing evidence for other adverse reproductive effects associated with aromatase inhibition by fenarimol.
Nadalje je sklenil, da razen zmanjšane plodnosti pri moških in učinkov, povezanih z zakasnelo kotitvijo, ni prepričljivih dokazov za druge škodljive učinke na razmnoževanje, povezane z inhibicijo aromataze, ki jo povzroča fenarimol.
Finally, the Scientific Committee agreed that the toxicological studies submitted permitted the establishment of a reliable ADI and AOEL.
Znanstveni odbor se je strinjal, da predložene toksikološke študije omogočajo določitev zanesljivih ADI in AOEL.
A second opinion [5] addressed the question whether the approach taken to calculate the Predicted Environmental Concentrations (PEC) in soil was adequate.
Drugo mnenje [5] je obravnavalo vprašanje, ali je bila metoda za izračun predvidenih okoljskih koncentracij v tleh (PECS) primerna.
The Committee proposed a combination of field dissipation and laboratory degradation data to calculate an accumulated soil PEC.
Znanstveni odbor je za izračun nakopičenih predvidenih okoljskih koncentracij v tleh predlagal kombinacijo podatkov o razpadu na prostem in o razkroju v laboratoriju.